Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis
NCT05371964Phase 1Active, not recruiting
- Sponsor
- Geron Corporation
- Start
- May 2022
- Primary completion
- Feb 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoints: Dose-limiting Toxicity at 28 days, Treatment-emergent Adverse Event up to 5 years and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05371964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371964.